Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript

Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript

Seeking Alpha • 18 hours ago

Vir Biotechnology Announces Proposed Public Offering of Common Stock

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer $200,000,000 of shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000.

Business Wire • 4 hours ago

These Analysts Boost Their Forecasts On Vir Biotechnology

Vir Biotechnology reported a fourth-quarter loss of 31 cents, beating the consensus loss of 41 cents. Sales reached $64.07 million, surpassing the consensus of $23.18 million.

Benzinga • 7 hours ago

What's Happening With VIR Stock?

Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer treatment, VIR-5500, along with encouraging Phase 1 results. This information, combined with an impressive revenue exceedance, is fostering considerable optimistic sentiment.

Forbes • 16 hours ago

Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish

Vir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer. VIR-5500 demonstrated a favorable safety profile and 45% ORR at higher doses, with Astellas providing $335M upfront and up to $1.37B in milestones. Recent licensing deals and a strong cash position ($781.6M) help offset 2025 net loss of $(438M), while pipeline advances target HDV and multiple oncology indications.

Seeking Alpha • 7 hours ago

Astellas collaborates with Vir to develop its experimental prostate cancer drug

Japan's Astellas and Vir Biotechnology said on Monday they will together develop and commercialize the U.S. drug developer's prostate cancer experimental drug.

Reuters • Feb 23, 2026

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN® dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy (NCT05997615). These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising an.

Business Wire • Feb 23, 2026

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. “This is a seminal moment for Vir Biotechnology, marked by key high-potential partnerships on two of our programs showcasing the strength of our pipeline and technology platforms. Today, we announced a global strategic collaboration with Astellas and compelling new Phase 1 data for VIR-5500, demonstr.

Business Wire • Feb 23, 2026

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.76 per share a year ago.

Zacks Investment Research • a day ago

Vir Biotech Catapults 65% On A $1.71 Billion Deal With Astellas

Vir stock catapulted late Monday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma.

Investors Business Daily • Feb 24, 2026